A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas

Exclusion Criteria

• •Prior autologous stem cell transplant ≤ 3 months before first dose or those who have not recovered
• •Symptomatic or uncontrolled ulcers (gastric or duodenal), particularly those with a history of and/or risk of perforation and gastrointestinal tract hemorrhages
• •Impaired cardiac function or clinically significant cardiac diseases
• •Poor bone marrow reserve as assessed by Investigator